Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook

• In February 2026, Supernus Pharmaceuticals reported fourth-quarter 2025 revenue of US$211.57 million and record full-year 2025 revenue of US$718.95 million, but swung to a full-year net loss of US$38.55 million and guided 2026 operating earnings to a range of US$0–US$30 million on expected total revenues of US$840–US$870 million.
• The results highlighted strong contributions from newer CNS products such as Qelbree, GOCOVRI, ZURZUVAE, and newly approved ONAPGO, alongside the completed Sage Therapeutics acquisition, even as higher costs and integration-related expenses weighed on profitability.
• We’ll now examine how the strong revenue guidance, underpinned by ONAPGO’s launch and Sage integration, may reshape Supernus’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Supernus Pharmaceuticals Investment Narrative Recap

To own Supernus, you need to believe its CNS portfolio can turn record 2025 revenues into sustainable profitability as newer drugs offset legacy headwinds. The latest results reinforce revenue momentum and 2026 growth guidance, but also underline that the immediate catalyst is execution on ONAPGO and Sage integration, while the biggest near term risk remains rising costs and the possibility that higher SG&A and R&D keep the company close to break even.

The most relevant update is Supernus’s 2026 outlook, which calls for US$840–US$870 million in revenue and operating earnings of US$0–US$30 million, including US$45–US$70 million from ONAPGO. This frames how much financial room the company has to invest behind Qelbree, GOCOVRI, ZURZUVAE and ONAPGO while still pushing late stage programs, and how sensitive that path is to any disappointment in growth products.

Yet even with record sales, investors should be aware that rising SG&A and R&D could keep GAAP profitability under pressure if…

Read the full narrative on Supernus Pharmaceuticals (it’s free!)

Supernus Pharmaceuticals’ narrative projects $837.3 million revenue and $55.4 million earnings by 2028. This requires 7.8% yearly revenue growth and a $6.5 million earnings decrease from $61.9 million today.

Uncover how Supernus Pharmaceuticals’ forecasts yield a $61.33 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$38 to about US$199 per share, showing very different expectations around Supernus’s potential. Against that backdrop, the company’s guidance for only modest 2026 operating earnings invites you to weigh upside from ONAPGO and Sage against the risk that higher costs hold back profit recovery.

Explore 3 other fair value estimates on Supernus Pharmaceuticals – why the stock might be worth 30% less than the current price!

The Verdict Is Yours

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

• A great starting point for your Supernus Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Supernus Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Supernus Pharmaceuticals’ overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com